NCT03067792View on ClinicalTrials.gov

FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

October 17, 2016

Study Completion Date

October 17, 2016

Conditions
Inoperable Gastric Cancer
Interventions
DRUG

5-fluorouracil, irinotecan and leucovorin

In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.

DRUG

docetaxel and cisplatin

In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle.

All Listed Sponsors
lead

Yonsei University

OTHER

NCT03067792 - FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter